# sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

> **NCT05332002** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 38 (estimated)

## Conditions studied

- Gastro-Intestinal Cancer

## Interventions

- **DRUG:** Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)

## Key facts

- **NCT ID:** NCT05332002
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332002, "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05332002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*